-
Eisai Releases Corporate Film “1 Percent, 1 Mission. Change the World.”
-
Human Capital Report 2024
-
Value Creation Report 2024
-
June 2, 2025
-
May 29, 2025
Eisai Obtains Favorable Decision in Patent Infringement Litigation Related to Lenvatinib in the U.S.
-
May 27, 2025
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO® (Lemborexant) in China
-
May 21, 2025
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
-
May 16, 2025
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro®
-
June 19, 2025
-
May 21, 2025
-
May 16, 2025
IR “Notice of Convocation of the 113th Ordinary General Meeting of Shareholders”
-
May 15, 2025
IR “Annual Financial Results Briefing for the Fiscal Year Ended March 31, 2025 (Material)”
-
May 15, 2025
IR “Annual Financial Report for the Fiscal Year Ended March 31, 2025”
-
February 19, 2025
Eisai’s Corporate Pension Fund Announces Adoption of “Asset Owner Principles”
-
October 3, 2024
EISAI NAMED AS ONE OF NEWSWEEK’S WORLD’S MOST TRUSTWORTHY COMPANIES 2024
-
June 21, 2024
Notification Regarding Revision of “Eisai Global Code of Conduct for Business Partners”
-
June 3, 2024
The Naito Museum of Pharmaceutical Science and Industry Listed as “Registered Museum”
-
April 8, 2024
Sustainability
32 countries 2.52billion tablets
Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of March 2025)
Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries
